Drug class in one race
MET drugs for Non-Small Cell Lung Cancer
14 tracked MET drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the MET page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
3 approved / phase 45 Phase 31 Phase 22 Phase 1/22 Phase 11 preclinical / unstaged
Head-to-head evidence: ABBV-400 vs Capmatinib · ABBV-400 vs Savolitinib · ABBV-400 vs Tepotinib · ASKC202 vs Capmatinib · ASKC202 vs Savolitinib · ASKC202 vs Tepotinib